IP Library Granted Patent US 10,117,885
Granted Patent B2
US 10,117,885 · App. 15/662,212 · Granted Nov 6, 2018

Chewable lipid supplements for treating pain and fibromyalgia

Inventor: Robert A. Settineri (Irvine, CA)
Assignee: ALLERGY RESEARCH GROUP, LLC
A61K31/702A23D9/013A23L29/10A23L29/244A23L33/105A23L33/115A23L33/12A61K9/006A61K9/0056A61K31/05A61K31/122A61K31/16A61K31/375A61K31/385A61K31/522A61K31/593A61K31/66A61K31/661A61K31/683A61K31/685A61K31/7028A61K31/716A61K31/733A61K33/22A61K38/28A61K38/44A61K38/446A61K45/06A61K47/12A61K47/24A61K47/26A61P21/00A61P39/06C12Y111/01006C12Y115/01001A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,117,885
App. No.
15/662,212
Granted
Nov 6, 2018
Kind
B2
Abstract

Composition, preferably, in the form of capsules or chewable wafers in quantities suitable for relieving the symptoms of fibromyalgia comprise formulations of phospholipids, specifically identified concentrations of phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, glycolipids and phosphatidylserine along with inulin and other desirable active ingredients are described.

Claims (21)

1. A composition comprising:

a) a base composition comprising a combination of inulin, and phospholipids in therapeutically effective amounts for relieving the symptoms of fibromyalgia, and

b) a carrier for the base composition comprising xylitol, a flavoring agent, stearic acid and/or vegetable stearate,

wherein the composition is formulated as a tablet, a capsule, a powder or an edible wafer, said composition effective, when consumed by an individual, for treating fibromyalgia and/or decreasing systemic and abdominal pain due to fibromyalgia, wherein the base composition comprises a combination of phospholipids comprising about 19-29% phosphatidylcholine, 15-25% phosphatidylethanolamine, 3.5-10% phosphatidic acid, 10-18% phosphatidylinositol, 2-10% phosphatidylglycerol, 10-20% glycolipids and phosphatidylserine.

2. The composition of claim 1 wherein an effective unit dose comprises at least about 1 g the phospholipids.

3. The composition of claim 2 in the form of an edible wafer.

4. The composition of claim 3 wherein an effective daily dosage is 4 wafers in a 24-hour period.

5. The composition of claim 1 further comprising a colorant.

6. A composition comprising:

a combination of inulin, and phospholipids in therapeutically effective amounts for relieving the symptoms of fibromyalgia, and

wherein the composition is formulated as a tablet, a capsule, a powder or an edible wafer, said composition effective, when consumed by an individual, for treating fibromyalgia and/or decreasing systemic and abdominal pain due to fibromyalgia, wherein the composition comprises a combination of phospholipids comprising about 19-29% phosphatidylcholine, 15-25% phosphatidylethanolamine, 3.5-10% phosphatidic acid, 10-18% phosphatidylinositol, 2-10% phosphatidylglycerol, 10-20% glycolipids and phosphatidylserine.

7. The composition of claim 6 comprising an effective unit dose containing at least about 1 g the phospholipids.

8. The composition of claim 7 wherein an effective daily dosage comprises delivery of four 1 g unit doses of the phospholipids in a 24-hour period.

9. A method for decreasing the symptoms of fibromyalgia and/or systemic and abdominal pain due to fibromyalgia, comprising delivering to an individual: a composition comprising:

a combination of inulin, and phospholipids in therapeutically effective amounts for relieving the symptoms of fibromyalgia, and

wherein the composition is formulated as a tablet, a capsule, a powder or an edible wafer, said composition effective, when consumed by an individual, for treating fibromyalgia and/or decreasing systemic and abdominal pain due to fibromyalgia, wherein the composition comprises a combination of phospholipids comprising about 19-29% phosphatidylcholine, 15-25% phosphatidylethanolamine, 3.5-10% phosphatidic acid, 10-18% phosphatidylinositol, 2-10% phosphatidylglycerol, 10-20% glycolipids and phosphatidylserine.

10. The method of claim 9 wherein an effective unit dose contains at least about 1 g of the phospholipids.

11. The method of claim 10 wherein an effective daily dosage comprises delivery of four 1 g unit doses of the phospholipids in a 24-hour period.

12. The composition of claim 1 wherein the base composition further includes caffeine.

13. The composition of claim 6 wherein said composition further includes caffeine.

14. The method of claim 9 wherein the composition further includes caffeine.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2020
From: ALLERGY RESEARCH GROUP, LLC.
To: NUTRITIONAL THERAPEUTICS, INC.
Reel/Frame 054027/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: SETTINERI, ROBERT A.
To: ALLERGY RESEARCH GROUP, LLC
Reel/Frame 044081/0354 →
Continuity (6)
Continuation In Part 15295878 · Oct 17, 2016
Continuation In Part 14815841 · Jul 31, 2015
Continuation In Part 14152938 · Jan 10, 2014
Continuation In Part 13208255 · Aug 11, 2011
Provisional Application 61750991 · Jan 10, 2013
Related Publication 20170319608A1 · Nov 9, 2017